Publications by authors named "Stephen B Howell"

Claim this Profile
P
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
Himangshu Sonowal, William G Rice, Raphael Bejar, Joo-Yun Byun, Seung Hyun Jung, Stephen B Howell

Cancer Res Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
Menghan Fang, Youfen Lin, Chaorong Xue, Kaiqin Sheng, Zegeng Guo, Stephen B Howell

Br J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer.
Clara Wong, Maria Carmen Mulero, Erika I Barth, Katherine Wang, Xiying Shang, Stephen B Howell

J Pharmacol Exp Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
Himangshu Sonowal, William G Rice, Stephen B Howell

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
William G Rice, Stephen B Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local

Mol Cancer Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer.
Alexander T Wenzel, Devora Champa, Hrishi Venkatesh, Si Sun, Cheng-Yu Tsai, Stephen B Howell

NPJ Syst Biol Appl· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.
Himangshu Sonowal, Hongying Zhang, William Rice, Stephen B Howell

Biochem Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors.
Songman Yu, Maria Carmen Mulero, Wannan Chen, Xiying Shang, Songyu Tian, Stephen B Howell

Bioconjug Chem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Sanghoon Lee, John Jun, William J Kim, Pablo Tamayo, Stephen B Howell

Anticancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA.
Byungji Kim, Si Sun, Judith A Varner, Stephen B Howell, Erkki Ruoslahti

Adv Mater· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy.
Alessandro Bertucci, Kang-Hoon Kim, Jinyoung Kang, Jonathan M Zuidema, Seo Hyeon Lee, Stephen B Howell

ACS Appl Mater Interfaces· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.
Maria T Proetto, Cassandra E Callmann, John Cliff, Craig J Szymanski, Dehong Hu, Stephen B Howell

ACS Cent Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Stephen B Howell

Mol Cancer Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Andrea Local, Hongying Zhang, Khalid D Benbatoul, Peter Folger, Xia Sheng, Stephen B Howell

Mol Cancer Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LGR5 and LGR6 in stem cell biology and ovarian cancer.
Adam J Schindler, Arisa Watanabe, Stephen B Howell

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder

Gynecol Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
Kristin M Bompiani, Cheng-Yu Tsai, Felix P Achatz, Janika K Liebig, Stephen B Howell

Metallomics· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy.
Maria T Proetto, Christopher R Anderton, Dehong Hu, Craig J Szymanski, Zihua Zhu, Stephen B Howell

ACS Nano· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.
Franco M Muggia, Andrea Bonetti, James D Hoeschele, Marcel Rozencweig, Stephen B Howell

J Clin Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).
Cheng-Yu Tsai, Janika K Liebig, Igor F Tsigelny, Stephen B Howell

Metallomics· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin inhibits MEK1/2.
Tetsu Yamamoto, Igor F Tsigelny, Andreas W Götz, Stephen B Howell

Oncotarget· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Kazuki N Sugahara, Pablo Scodeller, Gary B Braun, Tatiana Hurtado de Mendoza, Chisato M Yamazaki, Stephen B Howell

J Control Release· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrin αV control of Cu homeostasis and cisplatin sensitivity.
Xinjian Lin, Xiying Shang, Stephen B Howell

Cell Cycle· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1.
Xinjian Lin, Xiying Shang, Gerald Manorek, Mariama Fofana, Howell Stephen B

Oncoscience· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
Xiying Shang, Xinjian Lin, Stephen B Howell

Cell Commun Signal· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis